Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 July 2023 | Story NONSINDISO QWABE | Photo Supplied
Buhle Hlatshwayo
Buhle Hlatshwayo has been selected for the 2023 Fulbright Foreign Language Teaching Assistant (FLTA) Programme.

Buhle Hlatshwayo, a master’s student on the UFS Qwaqwa Campus, has been selected for the 2023 Fulbright Foreign Language Teaching Assistant (FLTA) programme. Despite initially doubting herself, she took a leap of faith and applied for the programme, which turned out to be a successful decision. The Fulbright Programme is a prestigious scholarship programme that provides opportunities for international educational exchanges. The programme’s overarching aim is to enhance intercultural relations across more than 160 countries.

Hlatshwayo will be teaching isiZulu at the University of Georgia in Athens, Georgia, for an academic year. She leaves South Africa at the end of July.

Hlatshwayo is currently pursuing her Master of Arts with specialisation in English on the UFS Qwaqwa Campus, where she also completed her undergraduate and honours degrees in the same field. Her research focuses on East African Arab migration narratives to the Global North, with a focus on exploring the legacies of colonialism. She is also a learning facilitator in the same department.

A prestigious opportunity 

A friend and colleague, Mxolisi Mabaso, encouraged her to apply, knowing her desire to explore opportunities abroad. 

“I am still in awe of how this opportunity came about, especially because someone else saw potential in me while I didn’t believe in myself. My good friend pushed me to apply, because he knew I always wanted the opportunity to go abroad. I am thrilled and honoured to be part of this prestigious programme. I am looking forward to experiencing the US culture and ways of being.”

On her love for English, Hlatshwayo said she has always been fond of the subject but never considered it as a potential career path. After completing her undergraduate degree, Dr Kudzayi Ngara, a Senior Lecturer in the Department of English on the Qwaqwa Campus, encouraged her to pursue an honour’s degree in English, which ultimately shaped her academic journey.

Professional and personal growth awaits

While in the US, Hlatshwayo said she is looking forward to immersing herself in American culture and pursuing courses in American studies. She aims to learn more about diverse cultural backgrounds and share her South African heritage and cultural values with the international community. She said this exchange of experiences and ideas will broaden her horizons and contribute to her academic and professional development.

“The opportunities would not present themselves if you were not capable. If you know your goals, seize any opportunity that will enable you to get there. I was not granted this opportunity because I’m smarter than everyone else, but because of how I articulated my genuine motivations with future goals and how the Fulbright programme will help me achieve them,” she said.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept